Medirom Healthcare Technologies Inc.: Form 20-F for the period ended Dec 31, 2024
Filed with the SEC on Apr 29, 2025 and accepted by EDGAR at Apr 29, 2025, 20:15 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2024-01-01 to 2024-12-31 | JPY 8.30bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months2024-01-01 to 2024-12-31 | JPY 6.05bn | us-gaap:CostOfRevenue |
| Gross profit | 12 months2024-01-01 to 2024-12-31 | JPY 2.25bn | us-gaap:GrossProfit |
| Selling, general and administrative | 12 months2024-01-01 to 2024-12-31 | JPY 2.24bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2024-01-01 to 2024-12-31 | −JPY 18.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2024-01-01 to 2024-12-31 | JPY 49.7m | us-gaap:InterestExpenseNonoperating |
| Income tax | 12 months2024-01-01 to 2024-12-31 | −JPY 90.5m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2024-01-01 to 2024-12-31 | JPY 148.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2024-01-01 to 2024-12-31 | JPY 28.52 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2024-01-01 to 2024-12-31 | JPY 29.13 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2024-01-01 to 2024-12-31 | 5,851,516 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2024-01-01 to 2024-12-31 | −JPY 1.33bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2024-01-01 to 2024-12-31 | JPY 71.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-12-31 | $2.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-12-31 | JPY 2.71bn | us-gaap:AssetsCurrent |
| Total assets | At period end2024-12-31 | JPY 8.09bn | us-gaap:Assets |
| Current liabilities | At period end2024-12-31 | JPY 4.18bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-12-31 | JPY 6.90bn | us-gaap:Liabilities |
| Long-term debt | At period end2024-12-31 | JPY 764.2m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2024-12-31 | JPY 620.8m | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | At period end2024-12-31 | JPY 491.7m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2024-12-31 | JPY 933.3m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2024-12-31 | 7,901,950 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001558370-25-005850. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.